Tag: Cancer

Multiplex Microarrays: The Next Generation ELISA

The hallmark of chronic diseases is the production of highly specific autoantibodies (1,2).  These autoantibodies are increasingly measured to guide clinical decision making.    The goal of these measurements is to define intracellular signal pathway activation profiles. These profiles can be integrated with clinical information to generate “biosignatures” for individual patients, the goal of which is personalized … Continued